Royal London Asset Management LTD Novo Cure LTD Transaction History

Royal London Asset Management LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$75.08 - $121.99 $2.67 Million - $4.33 Million	-35,510 Closed	0 $0
Q3 2021 Aug 16, 2022	BUY	$116.17 - $194.55 $4.13 Million - $6.91 Million	35,510 New	35,510 $4.12 Million
Q3 2021 Nov 02, 2021	SELL	$116.17 - $194.55 $4.13 Million - $6.91 Million	-35,510 Closed	0 $0
Q2 2021 Oct 18, 2022	BUY	$130.4 - $225.58 $4.63 Million - $8.01 Million	35,510 New	35,510 $7.88 Million
Q2 2021 Aug 16, 2022	BUY	$130.4 - $225.58 $4.63 Million - $8.01 Million	35,510 New	35,510 $7.88 Million
Q2 2021 Jul 14, 2021	SELL	$130.4 - $225.58 $4.6 Million - $7.96 Million	-35,277 Closed	0 $0
Q1 2021 Oct 17, 2022	BUY	$124.11 - $190.17 $4.38 Million - $6.71 Million	35,277 New	35,277 $4.67 Million
Q1 2021 Aug 16, 2022	BUY	$124.11 - $190.17 $4.38 Million - $6.71 Million	35,277 New	35,277 $4.67 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Royal London Asset Management LTD with notifications on news.